GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (NYSE:TEVA) » Definitions » Median PS Value

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Median PS Value

: $10.34 (As of Today)
View and export this data going back to 1990. Start your Free Trial

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Teva Pharmaceutical Industries's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $14.121. Teva Pharmaceutical Industries's 10-Year median PS Ratio is 0.7322. Therefore, the Median PS Value for today is $10.34.

As of today (2024-04-19), Teva Pharmaceutical Industries's share price is $12.86. Teva Pharmaceutical Industries's Median PS Value is $10.34. Therefore, Teva Pharmaceutical Industries's Price to Median PS Value for today is 1.24.

The historical rank and industry rank for Teva Pharmaceutical Industries's Median PS Value or its related term are showing as below:

TEVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31   Med: 0.52   Max: 1.26
Current: 1.24

During the past 13 years, the highest Price to Median PS Value of Teva Pharmaceutical Industries was 1.26. The lowest was 0.31. And the median was 0.52.

TEVA's Price-to-Median-PS-Value is ranked worse than
74.05% of 501 companies
in the Drug Manufacturers industry
Industry Median: 0.77 vs TEVA: 1.24

Teva Pharmaceutical Industries Median PS Value Historical Data

The historical data trend for Teva Pharmaceutical Industries's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.81 29.52 24.16 13.97 11.02

Teva Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.97 12.70 11.12 10.49 11.02

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries Price-to-Median-PS-Value Distribution

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Price-to-Median-PS-Value falls into.



Teva Pharmaceutical Industries Median PS Value Calculation

Teva Pharmaceutical Industries's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=14.121*0.7322
=10.34

10-Year Median PS Ratio is 0.7322.
Teva Pharmaceutical Industries's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.121.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Teva Pharmaceutical Industries  (NYSE:TEVA) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Teva Pharmaceutical Industries's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=12.86/10.34
=1.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Teva Pharmaceutical Industries Median PS Value Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Executives
Dov Bergwerk officer: Acting Chief Legal Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Vikki L Conway officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Varda Shalev director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Eliyahu Sharon Kalif officer: EVP, Chief Financial Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Amir Weiss officer: Chief Accounting Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Angus Grant officer: EVP, Business Development C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric A Hughes officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Sven Dethlefs officer: EVP Global Marketing&Portfolio 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric Drape officer: Executive VP Global Operations C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
David Matthew Stark officer: Exec. VP Chief Legal Officer 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Richard Daniell officer: Exec. VP, European Commercial 5 BASEL STREET, PO BOX 3190, PETACH TIKVA L3 4951033
Richard D Francis officer: President and CEO IM LANGACHER 44, GREIFENSEE V8 8606
Hafrun Fridriksdottir officer: Executive VP, Global R&D 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Eli Shani officer: EVP,Global Marketing&Portfolio C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Tal Zvi Zaks director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX